Norio Komatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Norio Komatsu has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Keiya Ozawa
Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan
10 shared publications - Tadashi Nagai
Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan
7 shared publications - Kazuo Muroi
Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital
6 shared publications Masaki Mori
Division of Hematology, Department of Medicine Jichi Medical School Minamikawachi Japan
6 shared publicationsYasusada Miura
Department of Hematology, Jichi Medical School, Minamikawachi, Tochigi, 329–0498, Japan
6 shared publicationsMie Uchida
Division of Hematology, Department of Medicine, Jichi Medical School, Minamikawachi-machi, Kawachi-gun, Tochigi-ken 329-0498, Japan
4 shared publications
Latest Publications
- Open Access
- 1 December 2012
- Published by Ross Science Publishers in Open Journal of Hematology
- Vol. 3 (1) , 1
Alteration of chromosome 13 abnormalities after therapeutic hematopoiesis recovery in myelodysplastic syndrome
- 1 December 2012
- Published by Ross Science Publishers in Open Journal of Hematology
- Vol. 3 (1) , 1
Open AccessAlteration of chromosome 13 abnormalities after therapeutic hematopoiesis recovery in myelodysplastic syndrome
- 1 November 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (11) , 2349-2351
Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes
A 40-year-old female with chronic myelogeneous leukemia (CML) in the chronic phase was treated with imatinib mesylate (STI571) because of interferon resistance. She achieved complete cytogenetic response but not complete molecular response 3 months after STI571 administration. Six months later, she developed severe liver damage without evidence of actively infectious hepatitis A, B, C, G, E, TT virus, Epstein-Barr virus or cytomegalovirus. A significant serum level of STI571 (107 ng/ml) was detected, although she had not taken the drug for 6 days. Liver biopsy demonstrated massive hepatic necrosis, consistent with drug-induced hepatitis. She achieved complete molecular response, although she did not take STI571 for 47 days after the development of hepatitis. These results suggest that both hepatitis and molecular response were associated with the serum STI571 concentration.
- 1 November 2004
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 45 (11) , 2349-2351
Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes
A 40-year-old female with chronic myelogeneous leukemia (CML) in the chronic phase was treated with imatinib mesylate (STI571) because of interferon resistance. She achieved complete cytogenetic response but not complete molecular response 3 months after STI571 administration. Six months later, she developed severe liver damage without evidence of actively infectious hepatitis A, B, C, G, E, TT virus, Epstein-Barr virus or cytomegalovirus. A significant serum level of STI571 (107 ng/ml) was detected, although she had not taken the drug for 6 days. Liver biopsy demonstrated massive hepatic necrosis, consistent with drug-induced hepatitis. She achieved complete molecular response, although she did not take STI571 for 47 days after the development of hepatitis. These results suggest that both hepatitis and molecular response were associated with the serum STI571 concentration.
- 1 October 2004
- Vol. 45 (10) , 1138-40
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
A 56-year-old woman with acute myeloid leukemia had two rapidly growing necrotizing nodules with ulcer formation on her head after the first course of consolidation therapy. Clinical features corresponding to sepsis (e.g., fever) appeared following the development of the skin lesion. Pseudomonas aeruginosa was isolated from the blood as well as pus of the lesion. Based on these findings, a diagnosis of ecthyma gangrenosum was made. Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features. Since Pseudomonas sepsis with ecthyma gangrenosum is associated with a high mortality rate, it is important to start immediate treatment with appropriate antibiotics.
- 1 October 2004
- Vol. 45 (10) , 1138-40
[Pseudomonas sepsis with ecthyma gangrenosum in an acute myeloid leukemia patient].
A 56-year-old woman with acute myeloid leukemia had two rapidly growing necrotizing nodules with ulcer formation on her head after the first course of consolidation therapy. Clinical features corresponding to sepsis (e.g., fever) appeared following the development of the skin lesion. Pseudomonas aeruginosa was isolated from the blood as well as pus of the lesion. Based on these findings, a diagnosis of ecthyma gangrenosum was made. Treatment with ciprofloxacin and gamma-globulin dramatically improved the patient's clinical features. Since Pseudomonas sepsis with ecthyma gangrenosum is associated with a high mortality rate, it is important to start immediate treatment with appropriate antibiotics.
- Open Access
- 1 July 2004
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 22 (4) , 609-616
Erythropoietin Overcomes Imatinib‐Induced Apoptosis and Induces Erythroid Differentiation in TF‐1/bcr‐abl Cells
Targeting BCR‐ABL tyrosine kinase by treatment with the selective inhibitor imatinib (formerly STI571, Gleevec) has proved to be highly efficient for inhibiting leukemic growth in vitro. In addition, in clinical trials, imatinib has produced high response rates in patients with chronic myeloid leukemia (CML) in chronic phase and blastic crisis. However, episodes of severe cytopenia were also frequently observed, leading to discontinuation of therapy in some cases. Therefore, it is important to examine whether administration of cytokines overcomes the adverse effects of imatinib in in vitro systems. In this study, we examine the effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and erythropoietin (EPO) on TF‐1/bcr‐abl (which was generated by transduction of a bcr‐abl fusion gene into the TF‐1 cell line) as a model system for CML with blastic crisis. Imatinib induced apoptosis in TF‐1/bcr‐abl cells but not in the parental TF‐1 cells. However, GM‐CSF, a survival factor of the parental TF‐1 cells, protected TF‐1/bcr‐abl cells from imatinib‐induced apoptosis in a dose‐dependent manner. Concomitantly, constitutive phosphorylation of Stat5 and FKHRL1 was significantly inhibited by imatinib, and the inhibition was canceled by the addition of GM‐CSF, accompanied by upregulation of Bcl‐xL and downregulation of p27/Kip1. In addition, although untreated TF‐1/bcr‐abl cells had lost responsiveness to both GM‐CSF and EPO and showed autonomous growth, GM‐CSF enhanced phosphorylation of Stat5 and FKHRL1 in these cells. Importantly, imatinib‐treated TF‐1/bcr‐abl cells differentiated into hemoglobin‐positive cells in the presence of EPO, as in the case for the parental TF‐1 cells. Taken together, imatinib‐treated CML cells may differentiate into mature cells in the presence of differentiation‐inducing cytokines such as EPO.
- 1 July 2004
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 22 (4) , 609-616
Open AccessErythropoietin Overcomes Imatinib‐Induced Apoptosis and Induces Erythroid Differentiation in TF‐1/bcr‐abl Cells
Targeting BCR‐ABL tyrosine kinase by treatment with the selective inhibitor imatinib (formerly STI571, Gleevec) has proved to be highly efficient for inhibiting leukemic growth in vitro. In addition, in clinical trials, imatinib has produced high response rates in patients with chronic myeloid leukemia (CML) in chronic phase and blastic crisis. However, episodes of severe cytopenia were also frequently observed, leading to discontinuation of therapy in some cases. Therefore, it is important to examine whether administration of cytokines overcomes the adverse effects of imatinib in in vitro systems. In this study, we examine the effects of granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and erythropoietin (EPO) on TF‐1/bcr‐abl (which was generated by transduction of a bcr‐abl fusion gene into the TF‐1 cell line) as a model system for CML with blastic crisis. Imatinib induced apoptosis in TF‐1/bcr‐abl cells but not in the parental TF‐1 cells. However, GM‐CSF, a survival factor of the parental TF‐1 cells, protected TF‐1/bcr‐abl cells from imatinib‐induced apoptosis in a dose‐dependent manner. Concomitantly, constitutive phosphorylation of Stat5 and FKHRL1 was significantly inhibited by imatinib, and the inhibition was canceled by the addition of GM‐CSF, accompanied by upregulation of Bcl‐xL and downregulation of p27/Kip1. In addition, although untreated TF‐1/bcr‐abl cells had lost responsiveness to both GM‐CSF and EPO and showed autonomous growth, GM‐CSF enhanced phosphorylation of Stat5 and FKHRL1 in these cells. Importantly, imatinib‐treated TF‐1/bcr‐abl cells differentiated into hemoglobin‐positive cells in the presence of EPO, as in the case for the parental TF‐1 cells. Taken together, imatinib‐treated CML cells may differentiate into mature cells in the presence of differentiation‐inducing cytokines such as EPO.
- 1 February 2004
- Vol. 45 (2) , 144-8
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male patient with refractory multiple myeloma resistant to thalidomide. In 1998, the patient was diagnosed as having multiple myeloma (IgG-kappa) and underwent chemotherapy, autologous hematopoietic cell transplantation and interferon therapy, but the disease recurred. In December 2002, thalidomide and high-dose dexamethasone therapy was initiated, and while this combination therapy was effective at first, the multiple myeloma became unresponsive. On 23 June 2003, bortezomib therapy with the following regime was therefore started: 2.2 mg (1.3 mg/m2) of bortezomib was injected intravenously on days 1, 4, 8 and 11, and after a one-week break, another cycle was performed. Starting on day 8 of the administration, the serum total protein, IgG, serum calcium and LDH levels decreased rapidly, and after day 45 of the administration, blood transfusion was no longer needed. Since this is the first report of the use of bortezomib in the treatment of refractory multiple myeloma in Japan, further monitoring of this patient will provide extremely valuable information for developing a therapy against this disease.
- 1 February 2004
- Vol. 45 (2) , 144-8
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
A proteasome inhibitor with a new molecular target (PS-341: bortezomib) was recently developed, and its efficacy in the treatment of refractory multiple myeloma has been reported in the United States. Here, we present a 54-year-old Japanese male patient with refractory multiple myeloma resistant to thalidomide. In 1998, the patient was diagnosed as having multiple myeloma (IgG-kappa) and underwent chemotherapy, autologous hematopoietic cell transplantation and interferon therapy, but the disease recurred. In December 2002, thalidomide and high-dose dexamethasone therapy was initiated, and while this combination therapy was effective at first, the multiple myeloma became unresponsive. On 23 June 2003, bortezomib therapy with the following regime was therefore started: 2.2 mg (1.3 mg/m2) of bortezomib was injected intravenously on days 1, 4, 8 and 11, and after a one-week break, another cycle was performed. Starting on day 8 of the administration, the serum total protein, IgG, serum calcium and LDH levels decreased rapidly, and after day 45 of the administration, blood transfusion was no longer needed. Since this is the first report of the use of bortezomib in the treatment of refractory multiple myeloma in Japan, further monitoring of this patient will provide extremely valuable information for developing a therapy against this disease.
- 1 September 2003
- Vol. 44 (9) , 968-70
[Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
A 35-year-old male with chronic myeloid leukemia in the accelerated phase received a peripheral blood stem cell transplant from his HLA-DR-mismatched mother. Graft-versus-host disease (GVHD) prophylaxis was with short-term methotrexate and tacrolimus. After transplantation, grade II skin acute GVHD occurred and was unsuccessfully treated with bolus methylprednisolone administration. The acute GVHD progressed to grade III of the skin, gut and liver, and mycophenolate mofetil (MMF) was accordingly administered at a daily dose of 2 g. This treatment resulted in a dramatic improvement in the clinical features of the acute GVHD. The patient suffered from hemorrhagic cystitis and several episodes of cytomegalovirus antigenemia. MMF may be useful for steroid-resistant acute GVHD despite an increasing risk of viral infections.
- 1 September 2003
- Vol. 44 (9) , 968-70
[Successful treatment of refractory acute GVHD with mycophenolate mofetil after peripheral blood stem cell transplantation from the patient's one locus-mismatched mother].
A 35-year-old male with chronic myeloid leukemia in the accelerated phase received a peripheral blood stem cell transplant from his HLA-DR-mismatched mother. Graft-versus-host disease (GVHD) prophylaxis was with short-term methotrexate and tacrolimus. After transplantation, grade II skin acute GVHD occurred and was unsuccessfully treated with bolus methylprednisolone administration. The acute GVHD progressed to grade III of the skin, gut and liver, and mycophenolate mofetil (MMF) was accordingly administered at a daily dose of 2 g. This treatment resulted in a dramatic improvement in the clinical features of the acute GVHD. The patient suffered from hemorrhagic cystitis and several episodes of cytomegalovirus antigenemia. MMF may be useful for steroid-resistant acute GVHD despite an increasing risk of viral infections.
- Open Access
- 1 May 2003
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 21 (3) , 315-321
Analysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR
The BCR/ABL tyrosine kinase inhibitor, imatinib, has shown substantial effects in blast crises of chronic myelogenous leukemia. However, most patients relapse after an initial clinical response, indicating that drug resistance is a major problem for patients being treated with imatinib. In this study, we generated a new imatinib‐resistant BCR/ABL‐positive cell line, KCL22/SR. The 50% inhibitory concentration of imatinib was 11‐fold higher in KCL22/SR than in the imatinib‐sensitive parental cell line, KCL22. However, KCL22/SR showed no mutations in the BCR/ABL gene and no increase in the levels of BCR/ABL protein and P‐glycoprotein. Furthermore, the level of phosphorylated BCR/ABL protein was suppressed by imatinib treatment, suggesting that mechanisms independent of BCR/ABL signaling are involved in the imatinib resistance in KCL22/SR cells. DNA microarray analyses demonstrated that the signal transduction‐related molecules, RAS p21 protein activator and RhoA, which could affect Ras signaling, and a surface tumor antigen, L6, were upregulated, while c‐Myb and activin A receptor were downregulated in KCL22/SR cells. Furthermore, imatinib treatment significantly suppressed the level of phosphorylated p44/42 in KCL22 cells but not in KCL22/SR cells, even when BCR/ABL was inhibited by imatinib. These results suggest that various mechanisms, including disturbance of Ras‐mitogen‐activated protein kinase signaling, are involved in imatinib resistance.
- 1 May 2003
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 21 (3) , 315-321
Open AccessAnalysis of Gene Expression Profiles in an Imatinib‐Resistant Cell Line, KCL22/SR
The BCR/ABL tyrosine kinase inhibitor, imatinib, has shown substantial effects in blast crises of chronic myelogenous leukemia. However, most patients relapse after an initial clinical response, indicating that drug resistance is a major problem for patients being treated with imatinib. In this study, we generated a new imatinib‐resistant BCR/ABL‐positive cell line, KCL22/SR. The 50% inhibitory concentration of imatinib was 11‐fold higher in KCL22/SR than in the imatinib‐sensitive parental cell line, KCL22. However, KCL22/SR showed no mutations in the BCR/ABL gene and no increase in the levels of BCR/ABL protein and P‐glycoprotein. Furthermore, the level of phosphorylated BCR/ABL protein was suppressed by imatinib treatment, suggesting that mechanisms independent of BCR/ABL signaling are involved in the imatinib resistance in KCL22/SR cells. DNA microarray analyses demonstrated that the signal transduction‐related molecules, RAS p21 protein activator and RhoA, which could affect Ras signaling, and a surface tumor antigen, L6, were upregulated, while c‐Myb and activin A receptor were downregulated in KCL22/SR cells. Furthermore, imatinib treatment significantly suppressed the level of phosphorylated p44/42 in KCL22 cells but not in KCL22/SR cells, even when BCR/ABL was inhibited by imatinib. These results suggest that various mechanisms, including disturbance of Ras‐mitogen‐activated protein kinase signaling, are involved in imatinib resistance.
- 7 March 2003
- Published by Wiley in Journal of Cellular Physiology
- Vol. 195 (2) , 290-297
Activation of extracellular signal‐regulated kinases ERK1 and ERK2 induces Bcl‐xL up‐regulation via inhibition of caspase activities in erythropoietin signaling
Erythropoietin (EPO) can rescue erythroid cells from apoptosis during erythroid development, leading to red cell production. However, the detailed mechanism of how EPO protects erythroid cells from apoptosis is still open to question. To address this problem, we used a human EPO‐dependent leukemia cell line UT‐7/EPO and normal erythroid progenitor cells. After deprivation of EPO, UT‐7/EPO cells underwent apoptosis, accompanied by down‐regulation of the Bcl‐xL protein. In addition, the cleaved products of caspase‐3, p11 and p21, and a few cleaved forms of inhibitor of caspase‐activated DNase (ICAD) were detected in these cells. When the cells were pre‐treated with the pancaspase inhibitor Z‐VAD‐FMK, the ratio of apoptotic cells was significantly reduced, suggesting that EPO protects the UT‐7/EPO cells from apoptosis via inhibition of caspase activities. When an MEK 1/2 inhibitor U0126 inhibited activities of extracellular signal‐regulated kinases (ERKs), the expression of Bcl‐xL protein was down‐regulated and subsequently apoptosis was induced. Interestingly, Z‐VAD‐FMK blocked U0126‐induced down‐regulation of Bcl‐xL protein and apoptosis, strongly suggesting that Bcl‐xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling. Importantly, these findings were also observed in normal erythroid progenitor cells. In conclusion, the activation of ERKs by EPO up‐regulates Bcl‐xL expression via inhibition of caspase activities, resulting in the protection of erythroid cells from apoptosis.
- 7 March 2003
- Published by Wiley in Journal of Cellular Physiology
- Vol. 195 (2) , 290-297
Activation of extracellular signal‐regulated kinases ERK1 and ERK2 induces Bcl‐xL up‐regulation via inhibition of caspase activities in erythropoietin signaling
Erythropoietin (EPO) can rescue erythroid cells from apoptosis during erythroid development, leading to red cell production. However, the detailed mechanism of how EPO protects erythroid cells from apoptosis is still open to question. To address this problem, we used a human EPO‐dependent leukemia cell line UT‐7/EPO and normal erythroid progenitor cells. After deprivation of EPO, UT‐7/EPO cells underwent apoptosis, accompanied by down‐regulation of the Bcl‐xL protein. In addition, the cleaved products of caspase‐3, p11 and p21, and a few cleaved forms of inhibitor of caspase‐activated DNase (ICAD) were detected in these cells. When the cells were pre‐treated with the pancaspase inhibitor Z‐VAD‐FMK, the ratio of apoptotic cells was significantly reduced, suggesting that EPO protects the UT‐7/EPO cells from apoptosis via inhibition of caspase activities. When an MEK 1/2 inhibitor U0126 inhibited activities of extracellular signal‐regulated kinases (ERKs), the expression of Bcl‐xL protein was down‐regulated and subsequently apoptosis was induced. Interestingly, Z‐VAD‐FMK blocked U0126‐induced down‐regulation of Bcl‐xL protein and apoptosis, strongly suggesting that Bcl‐xL expression is regulated by caspases which lies downstream of ERK activation pathway in EPO signaling. Importantly, these findings were also observed in normal erythroid progenitor cells. In conclusion, the activation of ERKs by EPO up‐regulates Bcl‐xL expression via inhibition of caspase activities, resulting in the protection of erythroid cells from apoptosis.
- Open Access
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6411-6419
A Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6411-6419
Open AccessA Member of Forkhead Transcription Factor FKHRL1 Is a Downstream Effector of STI571-induced Cell Cycle Arrest in BCR-ABL-expressing Cells
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (2) , 357-359
Massive Immune Hemolysis After Non-myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO-incompatibility
A 35-year-old male, blood group B, Rh(D)+ type, received an allogeneic peripheral blood stem cell (PBSC) transplant after a non-myeloablative regimen of fludarabine and cyclophosphamide for resistant γ δ cutaneous T-cell lymphoma (CTCL). The donor was his HLA-identical brother, blood group O, Rh(D)+ type. Graft-versus-host disease (GVHD) prophylaxis was performed with cyclosporine alone. On day +8, massive immune hemolysis occurred, followed by acute renal failure. Hemodialysis was performed eight times until recovery of renal function on day +24. The risk of delayed immune hemolysis after non-myeloablative allogeneic PBSC transplantation with minor ABO-incompatibility must be considered.
- 1 January 2003
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (2) , 357-359
Massive Immune Hemolysis After Non-myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation with Minor ABO-incompatibility
A 35-year-old male, blood group B, Rh(D)+ type, received an allogeneic peripheral blood stem cell (PBSC) transplant after a non-myeloablative regimen of fludarabine and cyclophosphamide for resistant γ δ cutaneous T-cell lymphoma (CTCL). The donor was his HLA-identical brother, blood group O, Rh(D)+ type. Graft-versus-host disease (GVHD) prophylaxis was performed with cyclosporine alone. On day +8, massive immune hemolysis occurred, followed by acute renal failure. Hemodialysis was performed eight times until recovery of renal function on day +24. The risk of delayed immune hemolysis after non-myeloablative allogeneic PBSC transplantation with minor ABO-incompatibility must be considered.